Mary Kay Inc. Joins Forces with the Equal Rights Trust to Pioneer Research on Gender Inequality in Algorithms and Artificial Intelligence
4.10.2021 11:00:00 EEST | Business Wire | Press release
Mary Kay Inc., a global leader in women’s empowerment, today announced a partnership with the Equal Rights Trust (ERT), an organization whose mission is to eliminate all forms of discrimination and ensure everyone can participate in society on an equal basis. Established in 2007, the Trust works in partnership to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. will help ERT jumpstart an innovative field of research on artificial intelligence and algorithms through a gender-based lens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005308/en/
Equal Rights Trust logo (Graphic: Mary Kay Inc.)
“As a company founded on the mission to enrich the lives of women everywhere, Mary Kay is constantly on the lookout for organizations we can partner with to make an impact for gender equality globally,” said Julia Simon, Chief Legal Officer and Chief Diversity Officer of Mary Kay Inc. “We’re excited to support Equal Rights Trust on their work to help advance equality by design and beyond forge a way forward to collaborations with the private sector. Our work with ERT is specifically focused on framing the new landscape of artificial intelligence and gender equality, a growing concern in the digital age.”
Mary Kay’s support to the ERT will pioneer a new field of research on the discriminatory impact of algorithmic systems. ERT has developed and promoted models of equality impact assessment, advocating an “equality by design” approach in public and private decision making as a means to ensure non-discrimination and equality of participation. An immediate priority is to launch an initiative to establish and address the emerging discriminatory impacts of algorithmic decision-making, specifically as it relates to gender.
“The use of algorithms and artificial intelligence is spreading,” said Ariane Adam, Deputy Director of the Equal Rights Trust. “These technologies are rapidly becoming essential parts of the analytical, communication, and even legal infrastructure for our societies. Despite the global proliferation of such systems, we are only just beginning to understand the flaws, limitations, and boundaries of algorithmic decision making, especially in terms of discrimination. We’re pleased to partner with Mary Kay to shine light on the potentially discriminatory impacts of using such technologies, in particular for women.”
The delivery of the initiative can be broken into three phases:
- Phase 1: research on emerging discriminatory impacts of the use of algorithmic-decision making in the areas of employment, access to loans, and access to housing, including a focus on the impact of women as a group particularly exposed to discrimination in these contexts.
- Phase 2: engagement with a wide-range of actors to develop advocacy strategies to call for an equality by design approach in the design, development, roll-out and monitoring of AI technologies.
- Phase 3: engaging with international, regional and national actors to set standards mandating an equality by design approach.
The partnership with the Equal Rights Trust is just the latest initiative supported by Mary Kay in 2021 to advocate for gender equality everywhere. For nearly 60 years, Mary Kay has been committed to empowering women and their families by partnering with organizations from around the world.
ABOUT EQUAL RIGHTS TRUST
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this mission, it works in partnership with equality defenders – civil society organizations (CSOs), lawyers, government representatives, and others committed to using law to create an equal world – providing them with the technical, strategic and practical support they need to work for the adoption and implementation of comprehensive equality laws. Since 2007, it has supported equality defenders in almost 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005308/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
